August 16, 2016 07:17 AM EDT
R&D

Hopes fad­ing, Onco­Genex ac­knowl­edges a PhI­II flop for can­cer drug

John Carroll

Editor & Founder

Any dwin­dling hopes that in­vestors still had in Onco­Genex $OGXI large­ly evap­o­rat­ed Tues­day morn­ing when the Seat­tle-based biotech re­port­ed that its late-stage ef­fort for cu­stirsen …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times